Fighting antibiotic resistance: Marrying new financial incentives to meeting public health goals

Health Affairs

Volumn 29, Issue 9, 2010, Pages 1689-1696

  Kesselheim, Aaron S ^a,b   Outterson, Kevin ^c  

^a Division of Pharmacoepidemiology and Pharmacoeconomics   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATORVASTATIN; AZITHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINEZOLID; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; AWARDS AND PRIZES; CLINICAL EFFECTIVENESS; CONSERVATION BIOLOGY; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG MISUSE; DRUG RESISTANT TUBERCULOSIS; EVIDENCE BASED PRACTICE; FINANCIAL MANAGEMENT; GASTRITIS; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HYPERCHOLESTEROLEMIA; INAPPROPRIATE PRESCRIBING; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PATENT; PENICILLIN RESISTANCE; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PUBLIC HEALTH SERVICE; REIMBURSEMENT; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; COST CONTROL; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; HUMANS; INFECTION CONTROL; ORPHAN DRUG PRODUCTION; PUBLIC HEALTH; REIMBURSEMENT MECHANISMS;

EID: 78649695936     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2009.0439     Document Type: Article

References (55)

1. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008; 6(5):751-63.
2. World Health Organization. WHO global strategy for containment of antimicrobial resistance [Internet]. Geneva: WHO; 2001 [cited 2010 Jun 17]. Available from: http://www.who.int/csr/resources/publications/drugresist/en/EGlobal_Strat.pdf
3. Geberding JL. Recent case of extensively drug resistant TB: CDC's public health response [Internet]. Statement in testimony before the House Committee on Homeland Security. Atlanta (GA): Centers for Disease Control and Prevention; 2007 Jun 6 [cited 2010 Jun 17]. Available from: http://hsc.house.gov/SiteDocuments/2007060612 5418-21114.pdf
4. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358(12):1271-81.
5. Tsuchimochi N, Takuma T, Shimono N, Nagasaki Y, Uchida Y, Harada M. Antimicrobial susceptibility and molecular epidemiological analysis of clinical strains of Pseudomonas aeruginosa. J Infect Chemother. 2008;14(2):99-104.
6. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13(12):1840-6.
7. Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of Gram-negative resistance. Crit Care Med. 2007; 35(1):89-95.
8. Asche C, McAdam-Marx C, Seal B, Crookston B, Mullins CD. Treatment costs associated with communityacquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother. 2008; 61(5):1162-8.
9. Capitano B, Leshem OA, Nightingale CH, Nicolau DP. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. J Am Geriatr Soc. 2003; 51(1):10-6.
10. Arias CA, Murray BE. Antibioticresistant bugs in the 21st century- a clinical super-challenge. N Engl J Med. 2009;360(5):439-43.
11. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews [Internet]. Alexandria (VA): IDSA; 2004 Jul [cited 2010 Jun 17]. Available from: http://www.fda.gov/ohrms/dockets/dockets/04s0233/04s-0233-c000005-03-IDSA-vol1.pdf
12. Levy SB. Antibiotic and antiseptic resistance: impact on public health. Pediatr Infect Dis J. 2000; 19(10 Suppl):S120-2.
13. Grossman CM. The first use of penicillin in the United States. Ann Intern Med. 2008;149(2):135-6.
14. Barber M. Staphylococcal infection due to penicillin-resistant strains. Br Med J. 1947;2:863-5.
15. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges, and responses. Nat Med. 2004;10(12 Suppl):S122-9.
16. Switzer GE, Halm EA, Chang CC, Mittman BS, Walsh MB, Fine MJ. Physician awareness and selfreported use of local and national guidelines for community-acquired pneumonia. J Gen Intern Med. 2003;18(10):816-23.
17. Saver R. In tepid defense of population health: physicians and antibiotic resistance. Am J Law Med. 2008;34(4):431-91.
18. Coenen S, Michiels B, Renard D, Denekens J, Van Royen P. Antibiotic prescribing for acute cough: the effect of perceived patient demand. Br J Gen Pract. 2006;56(524):183-90.
19. U.S. Food and Drug Administration, Division of Drug Marketing, Advertising, and Communication. Warning letter [Internet]. Silver Spring (MD): FDA; 2005 Jul 20 [cited 2010 Jun 17]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/EnforcementActivities byFDA/WarningLettersandNoticeof ViolationLetterstoPharmaceutical Companies/ucm054813.pdf
20. United States et al. ex rel. Blair Collins v. Pfizer, Inc. Civ. No. 04-11780-DPW (D. Mass).
21. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibioticresistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46:155-64.
22. Leeb M. Antibiotics: a shot in the arm. Nature. 2004;431(7011):892-3.
23. Wenzel RP. The antibiotic pipeline: challenges, costs, and values. N Engl J Med. 2004;351:523-6.
24. Finch R, Hunter PA. Antibiotic resistance: action to promote new technologies. J Antimicrob Chemother. 2006;58(Suppl 1):i3-22.
25. Pollack A. For profit, industry seeks cancer drugs. New York Times. 2009 Sep 2.
26. Malik RK, Montecalvo MA, Reale MR, Li K, Maw M, Munoz JL, et al. Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit. Pediatr Infect Dis J. 1999;18: 352-6.
27. Wertheim HF, Vos MC, Boelens HA, Voss A, Vandenbroucke-Grauls CM, Meester MH, et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands. J Hosp Infect. 2004;56:321-5.
28. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillinresistant Staphylococcus aureus central line-associated bloodstream infections in U.S. intensive care units, 1997-2007. JAMA. 2009;301: 727-36.
29. Solomon DH, Van Houten L, Glynn RJ, Baden L, Curtis K, Schrager H, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med. 2001;161(15):1897-902.
30. Schaffer K, Fitzgerald S, Gonzalez-Sanchez Z, Fenelon L. Do educational interventions improve management of patients with community-acquired pneumonia? J Healthc Qual. 2006;28(6):7-12.
31. Lesprit P, Brun-Buisson C. Hospital antibiotic stewardship. Curr Opin Infect Dis. 2008;21(4):344-9.
32. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, et al. Isolation of patients in single rooms or cohorts to reduce spread of MRSA in intensive-care units. Lancet. 2005;365(9456):295-304.
33. Wald HL, Kramer AM. Nonpayment for harms resulting from medical care: catheter-associated urinary tract infections. JAMA. 2007;298: 2782-4.
34. U.S. Government Accountability Office. New drug development. Washington (DC): GAO; 2006 Nov [cited 2010 Jun 17]. Available from: http://www.gao.gov/new.items/d0749.pdf
35. Livermore D. Can better prescribing turn the tide of resistance? Nat Rev Microbiol. 2004;2:73-8.
36. Outterson K. The vanishing public domain: antibiotic resistance, pharmaceutical innovation, and intellectual property law. Univ Pittsbg Law Rev. 2005;67:67-123.
37. Kades E. Preserving a precious resource: rationalizing the use of antibiotics. Northwest Univ Law Rev. 2005;99:611-75.
38. Outterson K, Samora JR, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet Infect Dis. 2007; 7:559-66.
39. Sonderholm J. Wild-card patent extensions as a means to incentivize research and development of antibiotics. J Law Med Ethics. 2009;37: 240-6.
40. Food and Drug Administration Amendments Act of 2007, section 1112 (2007)
41. Love J, Hubbard T. The big idea: prizes to stimulate R&D for new medicines. Chic Kent Law Rev. 2007;82:1519-54.
42. Medical Innovation Prize Act, S. 2210, 110th Cong., 1st sess. (2007).
43. Outterson K. The legal ecology of resistance: the role of antibiotic resistance in pharmaceutical innovation. Cardozo Law Rev. 2010;31: 613-78.
44. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197:1079-81.
45. Smith I, Nathan C, Peavy HH. Progress and new directions in genetics of tuberculosis: an NHLBI working group report. Am J Respir Crit Care Med. 2005;172(12):1491-6.
46. Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia. Lancet. 2008;372: 1403-9.
47. Peters NK, Dixon DM, Holland SM, Fauci AS. The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance. J Infect Dis. 2008;197(8): 1087-93.
48. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis. 2005;5:115-9.
49. Powers JH. Antimicrobial drug development: the past, the present, and the future. Clin Microbiol Infect. 2004;10(Suppl 4):23-31.
50. Tillotson G. Pneumonia workshop raises more questions than answers. Lancet Infect Dis. 2008;8:221.
51. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov. 2003;2:695-702.
52. Outterson K, Powers JH, Gould IM, Kesselheim AS. Questions about the "10 X 20" initiative. Clin Infect Dis. Forthcoming 2010.
53. Currently, consumers can purchase a generic antibiotic for $4 in many retail pharmacies, and a few pharmacies have experimented with offering the same antibiotics at no charge. Parker-Pope T. Free antibiotics may contribute to drug resistance, officials say. New York Times. 2009 Mar 4;A22.
54. Kmietowicz Z. NICE proposes to withdraw Alzheimer's drugs from NHS. BMJ. 2005;330:495.
55. Doran E, Alexander HD. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia. J Public Health Policy. 2008; 29(1):106-20.